Opus Genetics (IRD) Net Cash Flow (2010 - 2026)

Opus Genetics (IRD) has 17 years of Net Cash Flow data on file, last reported at $14.9 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $14.9 million, up 29.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.2 million (up 438.37% YoY), and the FY2025 annual result was $14.8 million, up 173.19% from the prior year.
• Net Cash Flow rose to $14.9 million in Q1 2026 per IRD's latest filing, from $14.3 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $28.8 million in Q4 2022 and troughed at -$9.4 million in Q2 2025.
• A 5-year average of $2.1 million and a median of -$2.2 million in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow soared 1160.03% in 2022, then tumbled 681.6% in 2024.
• A 5-year view of Net Cash Flow shows it stood at $28.8 million in 2022, then slumped by 71.68% to $8.2 million in 2023, then sank by 177.43% to -$6.3 million in 2024, then jumped by 326.21% to $14.3 million in 2025, then increased by 4.15% to $14.9 million in 2026.
• Business Quant data shows IRD's Net Cash Flow at $14.9 million in Q1 2026, $14.3 million in Q4 2025, and -$1.6 million in Q3 2025.